Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes

New England Journal of Medicine

Volumn 345, Issue 4, 2001, Pages 248-255

  Ellis, Charles N ^a   Krueger, Gerald G ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CD2 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOMODULATING AGENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DELAYED HYPERSENSITIVITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; VERTIGO;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIGENS, CD45; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035954670     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200107263450403     Document Type: Article

References (23)

1. An overview of psoriasis
2. Treatment of psoriasis
3. Cyclosporine for plaque-type psoriasis: Results of a multidose, double-blind trial
4. Duration of remission of psoriasis therapies
5. T-cell activation via CD2 [T, gpS0] molecules: Accessory cells are required to trigger T cell activation via CD2-D66 plus CD2-9.6/T11(1) epitopes
6. Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation
7. The tyrosine kinase activity of p56lck is increased in human T cells activated via CD2
8. The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates
9. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: Cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers
10. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: Structure/function analysis in vitro and in human CD2 transgenic mice
11. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival
12. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses
13. +) in both normal and diseased human skin
14. Proliferating cells in psoriatic dermis are comprised primarily of T-cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells
15. Severe psoriasis - Oral therapy with a new retinoid
16. Duration of remission during maintenance cyclosporine therapy for psoriasis: Relationship to maintenance dose and degree of improvement during initial therapy
17. Inflammatory skin diseases, T cells, and immune surveillance
18. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy
19. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells
20. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia
21. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
22. 389IL-2): A phase I clinical study and histopathologic assessment